Biodesix (BDSX) Stock Price, News & Analysis

Company Overview

Biodesix, Inc. is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.

The company’s flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies. Building on that platform, Biodesix has introduced GeneStrat®, a targeted next-generation sequencing assay that detects key genomic mutations in circulating tumor DNA to support precision oncology. Together, these tests are used by oncologists and pulmonologists to refine treatment plans, monitor disease progression and ultimately improve patient outcomes. Biodesix continues to invest in research and development, exploring new liquid biopsy and proteomic applications across additional indications.

Founded in 2004, Biodesix went public in 2015 and trades on the NASDAQ under the ticker BDSX. The company primarily serves healthcare providers and pharmaceutical partners in the United States, with emerging collaborations aimed at expanding its customer base in Europe and Asia. Biodesix has established strategic alliances with leading pharmaceutical and biotechnology firms to co-develop diagnostic assays alongside novel therapies, reinforcing its role in the precision medicine ecosystem.

Under the leadership of David P. Brunel, President and Chief Executive Officer, Biodesix is focused on broadening its test menu, enhancing laboratory automation and pursuing regulatory clearances for new indications. The company’s ongoing efforts in proteomic and genomic innovation position it as a key player in the rapidly evolving field of oncology diagnostics.

Key Stats

• Today's Range: $22.45 to $23.93
• 50-Day Range: $14.80 to $24.50
• 52-Week Range: $5.26 to $25.00
• Volume: 80,899 shs
• Average Volume: 69,984 shs
• Market Capitalization: $243.46 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $28.67
• Consensus Rating: Moderate Buy

Biodesix Stock Analysis - MarketRank™

Biodesix scored higher than 63% of companies evaluated by MarketBeat, and ranked 263rd out of 902 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Biodesix has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 1 strong buy rating, 3 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Biodesix has a consensus price target of $28.67, representing about 22.0% upside from its current price of $23.50.

Amount of Analyst Coverage

Biodesix has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Biodesix are expected to grow in the coming year, from ($2.91) to ($1.85) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Biodesix is -7.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Biodesix is -7.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Biodesix has a P/B Ratio of 26.70. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.11% of the float of Biodesix has been sold short.

Short Interest Ratio / Days to Cover

Biodesix has a short interest ratio ("days to cover") of 2.19, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Biodesix has recently increased by 59.32%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Biodesix does not currently pay a dividend.

Dividend Growth

Biodesix does not have a long track record of dividend growth.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.44

News Sentiment

Biodesix has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 16 news articles for Biodesix this week, compared to 3 articles on an average week.

Search Interest

Only 2 people have searched for BDSX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

1 people have added Biodesix to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Biodesix insiders have not sold or bought any company stock.

Percentage Held by Insiders

23.20% of the stock of Biodesix is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

20.96% of the stock of Biodesix is held by institutions.

Company Calendar

• Last Earnings: 8/05/2026
• Today: 8/08/2026
• Canaccord Genuity's 46th Annual Growth Conference: 8/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Providers & Services
• Sub-Industry: Healthcare Services
• Current Symbol: NASDAQ:BDSX
• CIK: 1439725
• Web: www.biodesix.com
• Phone: 303-417-0500
• Fax: N/A
• Employees: 220
• Year Founded: 2005

Price Target and Rating

• Average Price Target for Biodesix: $28.67
• High Price Target: $32.00
• Low Price Target: $27.00
• Potential Upside/Downside: +22.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($4.06)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$35.26 million
• Net Margins: -26.97%
• Pretax Margin: -26.97%
• Return on Equity: -788.19%
• Return on Assets: -30.33%

Debt

• Debt-to-Equity Ratio: 5.12
• Current Ratio: 2.85
• Quick Ratio: 2.82

Sales & Book Value

• Annual Sales: $88.50 million
• Price / Sales: 2.75
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.88 per share
• Price / Book: 26.70

Miscellaneous

• Outstanding Shares: 10,360,000
• Free Float: 7,953,000
• Market Cap: $243.46 million
• Optionable: No Data
• Beta: 0.56